Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImmunoGen, Inc.IMGN · Entity 94428 | Executive VP & CSO | February 22, 2019 | February 25, 2019 |
| ProMIS Neurosciences Inc.PMN · Entity 6643 | Director | July 07, 2022 | July 07, 2022 |
| Q32 Bio Inc.FIXX · Entity 5594 | Director | June 15, 2022 | June 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImmunoGen, Inc.
Report date February 22, 2019 · Filed February 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 199,413 |
Reported balance
After 2018-02-22 transaction · row 1
1 source rowRow 1 · 2018-02-22 · Sale · Disposed 36,643 · Balance 199,413 F2: The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person. F1: Weighted average price of shares sold. |
Filing footnotes · ownership attribution and instrument terms
F1: Weighted average price of shares sold.
F2: The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person.
ProMIS Neurosciences Inc.
Report date July 07, 2022 · Filed July 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2026-10-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-07-07 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Conversion or exercise price is in Canadian dollars. F2: The option agreement provides that 25% of the options vest immediately, with the remainder vesting ratably over the next three quarters beginning January 17, 2017. The option was granted on October 17, 2016. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.20 · Expires 2031-03-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-07-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Conversion or exercise price is in Canadian dollars. F3: The option agreement provides that 25% of the options vest immediately, with the remainder vesting ratably over the next three quarters beginning June 30, 2021. The option was granted on March 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Conversion or exercise price is in Canadian dollars.
F2: The option agreement provides that 25% of the options vest immediately, with the remainder vesting ratably over the next three quarters beginning January 17, 2017. The option was granted on October 17, 2016.
F3: The option agreement provides that 25% of the options vest immediately, with the remainder vesting ratably over the next three quarters beginning June 30, 2021. The option was granted on March 30, 2021.
Q32 Bio Inc.
Report date June 15, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.88 · Expires 2032-06-15 | Direct | 18,000 |
Reported balance
After 2022-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 18,000 · Balance 18,000 F1: This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2022 Filed Jun 17, 2022 16:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000899243-22-023067 · doc4.xml · derivative · entry 1 Gregory Richard J. · CIK 0001629767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 15, 2023 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 17:41 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0000899243-21-025335 · doc4.xml · derivative · entry 1 Gregory Richard J. · CIK 0001629767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 17, 2022 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 17:27 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0000899243-20-016392 · doc4.xml · derivative · entry 1 Gregory Richard J. · CIK 0001629767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 10, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| November 18, 2019 Filed Jan 29, 2020 18:43 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionEmployee Stock Option · Derivative | 10,806 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0000899243-20-002311 · doc4.xml · derivative · entry 2 Gregory Richard J. · CIK 0001629767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,806 shares Expires 2025-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 18, 2019 Filed Jan 29, 2020 18:43 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCOMMON STOCK | 10,806 | $0.03 | $324.18 |
DisclosureSEC source: 0000899243-20-002311 · doc4.xml · nonDerivative · entry 1 Gregory Richard J. · CIK 0001629767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 17:11 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 15,580 | $0.00 Strike: $19.51 | $0.00 |
DisclosureSEC source: 0000899243-19-016228 · doc4.xml · derivative · entry 1 Gregory Richard J. · CIK 0001629767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,580 Underlying: Common Stock · 15,580 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 6, 2020 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through each such vesting date. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 16:37 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock option (right to buy) · Derivative | 289,150 | $5.25 Strike: $5.25 | $1,518,037.50 |
DisclosureSEC source: 0001179110-19-001232 · edgar.xml · derivative · entry 1 Gregory Richard J. · CIK 0001629767 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,150 Underlying: Common stock · 289,150 shares Expires 2029-01-31 F1 · derivative.exercise_date: Exercisable in three equal installments over the next three years starting on the first year anniversary of the grant. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 08:47 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 3,038 | $5.27 | $16,013.91 |
DisclosureSEC source: 0001179110-19-000546 · edgar.xml · nonDerivative · entry 1 Gregory Richard J. · CIK 0001629767 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,056 F2 · shares: The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person on December 11, 2015. F1 · price: Weighted average price of shares sold. Read SEC document |
| March 27, 2018 Filed Mar 29, 2018 19:27 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee stock option · Derivative | 31,160 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-18-008924 · doc4.xml · derivative · entry 1 Gregory Richard J. · CIK 0001629767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,160 Underlying: Common Stock · 31,160 shares Expires 2028-03-27 F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019. Read SEC document |
| February 22, 2018 Filed Feb 25, 2019 10:10 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 36,643 | $5.60 | $205,200.80 |
DisclosureSEC source: 0001179110-19-002466 · edgar.xml · nonDerivative · entry 1 Gregory Richard J. · CIK 0001629767 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,413 F2 · shares: The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person. F1 · price: Weighted average price of shares sold. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 11:45 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 34,486 | $10.88 | $375,207.68 |
DisclosureSEC source: 0001179110-18-002670 · edgar.xml · nonDerivative · entry 1 Gregory Richard J. · CIK 0001629767 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,094 F2 · shares: The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person. F1 · price: Weighted average price of shares sold. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 16:03 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock option (right to buy) · Derivative | 256,500 | $10.65 Strike: $10.65 | $2,731,725.00 |
DisclosureSEC source: 0001179110-18-002367 · edgar.xml · derivative · entry 1 Gregory Richard J. · CIK 0001629767 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,500 Underlying: Common stock · 256,500 shares Expires 2028-02-28 F1 · derivative.exercise_date: Exercisable in three equal installments over the next three years starting on the first year anniversary of the grant. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 15:59 UTC Amendment | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 2,904 | $6.64 | $19,286.92 |
DisclosureSEC source: 0001179110-18-000728 · edgar.xml · nonDerivative · entry 1 Gregory Richard J. · CIK 0001629767 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,577 F3 · date: Due to clerical error, the year 2017 was indicated on the original filing when it should have been 2018. This amendment corrects those dates. F2 · shares: The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person on December 11, 2015. F1 · price: Weighted average price of shares sold. Read SEC document |
| February 21, 2017 Filed Feb 23, 2017 15:21 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 237,250 | $2.47 | $586,007.50 |
DisclosureSEC source: 0001179110-17-003020 · edgar.xml · nonDerivative · entry 1 Gregory Richard J. · CIK 0001629767 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,481 F1 · shares: These shares are restricted stock which vest annually in three equal installments commencing on February 21, 2018. Read SEC document |
| January 08, 2017 Filed Jan 8, 2018 15:36 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | SaleCommon Stock | 2,904 | $6.64 | $19,286.92 |
DisclosureSEC source: 0001179110-18-000677 · edgar.xml · nonDerivative · entry 1 Gregory Richard J. · CIK 0001629767 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,577 F2 · shares: The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person on December 11, 2015. F1 · price: Weighted average price of shares sold. Read SEC document |
| November 02, 2016 Filed Nov 3, 2016 12:55 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | PurchaseCommon Stock | 16,600 | $1.78 | $29,597.80 |
DisclosureSEC source: 0001179110-16-031111 · edgar.xml · nonDerivative · entry 1 Gregory Richard J. · CIK 0001629767 · Executive VP & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,231 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.